Another phase III study tested RSR13 (efaproxiral) in combination with WBRT. RSR13 binds to hemoglobin and reduces its affinity for oxygen thus increasing tissue pO2. In this study of WBRT plus supplemental oxygen with or without RSR13, overall survival increased from 4.6 months to 8.7 months in the subset of breast cancer patients. The role of RSR13 is currently being evaluated for patients with brain metastases from breast cancer.110
http://www.irsa.org/metastatic%20guideline.pdf